奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效

Curative Effect of Oxaliplatin Combined with S-1 capsule in the Treatment of Advanced Colorectal Carcinoma

目的:探讨奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效。方法:非盲法随机对照方法将患者分成试验组和对照组,各27例。试验组患者使用奥沙利铂联合替吉奥胶囊治疗,对照组患者使用奥沙利铂治疗,均为4个周期。评价两组治疗后的临床疗效和不良反应。结果:试验组:CR 1例,PR 11例,SD 10例,PD 5例。(CR+PR)RR 44.4%。中位疾病进展时间(TTP)9.5个月,中位生存期(MST)19.1个月。对照组:CR 0例,PR 5例,SD 8例,PD 15例。(CR+PR)RR 18.5%。中位疾病进展时间(TTP)8.6个月,中位生存期(MST)16.9个月。主要不良反应为血液毒性、胃肠道反应、外周神经炎及肝功能异常。试验组白细胞下降15例,对照组12例,试验组贫血发生为13例,对照组的为21例,试验组恶心、呕吐发生为18例,对照组为24例,试验组便秘发生为8例,对照组为15例,差异有统计学意义(P<0.05)。结论:奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者相比单独使用奥沙利铂更加有效,更具优越性,不良反应更少,患者的生存质量得以改善,值得临床上推广应用。

Objective： To evaluate the curative effect of oxaliplatin combined with S-1 capsule in the treatment of advanced colorectal carcinoma. Methods： Non-blinded randomized controlled trial was used, 27 cases were in the test group, and were treated with oxaliplatin combined with S-1 capsule; 27 cases which were only treated with oxaliplatin were in the control group. The curative effect and side effects were evaluated after 4 cycles of treatment. Result： Test group： CR was observed in 1 patient, PR in 11 patients, SD in 10 patients, and PD in 5 patients. The total effective rate was 44.4%. The median time to disease progression （TTP） were 9.5 months, median survival time （MST） were 19.1 months. Control group： CR was observed in no patient, PR in 9 patients,SD in 10 patients, and PD in 8 patients. The total effective rate was 18.5%. The median time to disease progression （TTP） was 8.6 months, and median survival time （MST） was 16.9 months. Major side effects were hematotoxicity, gastrointestinal reaction, peripheral neuritis and abnormal liver function. The leukopenia was found in 15 cases in the test group and in 12 cases in control group. The incidence of anemia in test group was 13 cases, in comparison with the 21 cases in control group. The incidence of nausea or vomiting in test group was 18 cases, in comparison with the 24 cases in control group. The incidence of constipation in test group was 8 cases,in comparison with the 15 cases in control group. The differences were statistically significant （P〈0.05）. Conclusion： Oxaliplatin combined with S-1 capsule is effective, advantageous and has lower side effects in comparison with using oxaliplatin alone in the treatment of patients with colorectal cancer. It can improve the life quality of the patients and is worthy of clinical application.